Real-life data concerning dupilumab effectiveness and safety in adolescents (≥12 to <18 years) with moderate-to-severe atopic dermatitis (AD) are rarely reported.1 In the adolescent phase III randomized, placebo-controlled, clinical trial (LIBERTY AD ADOL)2 and the phase IIa and subsequent phase III open label extension (LIBERTY AD PED-OLE)3 dupilumab showed significant signs and symptoms improvement at week-16, with a good safety profile. Herein, we report our real-life experience on AD adolescents treated with dupilumab.

Dupilumab in adolescents with moderate-to-severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic

Patruno, C;
2021-01-01

Abstract

Real-life data concerning dupilumab effectiveness and safety in adolescents (≥12 to <18 years) with moderate-to-severe atopic dermatitis (AD) are rarely reported.1 In the adolescent phase III randomized, placebo-controlled, clinical trial (LIBERTY AD ADOL)2 and the phase IIa and subsequent phase III open label extension (LIBERTY AD PED-OLE)3 dupilumab showed significant signs and symptoms improvement at week-16, with a good safety profile. Herein, we report our real-life experience on AD adolescents treated with dupilumab.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12317/70969
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 24
social impact